Teva Pharmaceutical Industries (TEVA) - Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

Logo perusahaan publik Teva Pharmaceuticals (TEVA)

The EV/EBITDA multiple chart demonstrates the pressure of capital rates, with the 14.69 value showing the most recent figure. Teva Pharmaceutical Industries (TEVA) faces massive borrowings and opioid-related litigation. Colossal debt and regulatory pressure are slowing operating profit growth. Currently, the holding is successfully reducing its debt load by introducing innovative biologics in neurology to diversify its portfolio.

TEVA Teva Pharmaceutical Industries Ltd.: Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ing interval 23.11.2025 - 17.11.2026

Rincian analitis perusahaan Teva Pharmaceutical Industries

- rega saiki lan proyeksi nilai saham:
Pambiji fundamental perusahaan:Teva Pharmaceutical Industries Ltd. TEVA
Sampel barang Teva Pharmaceutical Industries Limited

The multiple compares the total enterprise value, including net debt, against EBITDA to measure the payback period of assets. The formula is highly sensitive to changes in operating cash flow and debt service costs. The valuation trend based on the EV/EBITDA multiple reflects market confidence in the issuer's financial stability. For Teva Pharmaceutical Industries (TEVA), this is a key indicator of the effectiveness of Richard Francis's strategy to reduce debt leverage and pivot toward innovative drugs.